Rennova Health, Inc. (RNVA) ended last trading session with a change of 0.84 percent. It trades at an average volume of 3.73M shares versus 8.75M shares recorded at the end of last trading session. The share price of $0.08 is at a distance of 4.63 percent from its 52-week low and down -92.78 percent versus its peak. The company has a market cap of $4.7M and currently has 56.18M shares outstanding. The share price is currently -17.23 percent versus its SMA20, -23.83 percent versus its SMA50, and -77.1 percent versus its SMA200. The stock has a weekly performance of 2.7 percent and is 0.84 percent year-to-date as of the recent close.
January 05, 2017 — Rennova Health, Inc. (RNVA), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, provides the following summary of its recent progress, as well as commentary on its business strategy and milestones for 2017.
“We took a number of steps in 2016 to address challenges in the substance abuse testing sector, and we have begun to see the initial signs of success that will be instrumental to a return to top-line growth. Indeed, our fourth quarter was the best quarter for new sales in more than a year, and included several new clients, as well as a number of returning clients,” said Seamus Lagan, Rennova’s chief executive officer. “We have diversified our business model and have secured in-network contracts with a number of third-party payers. We have moved from a concentration in substance abuse testing services in a single geographic location to providing a range of diagnostic services across the nation to an expanding and varied customer base.
“As well as recent successes in the substance abuse and pain management sector, we have initiated a relationship with a clinical research organization and we expect to begin generating sales from them in the first half of 2017. We have secured a contract with a service-disabled, veteran-owned small business to be their exclusive provider of lab services and are servicing initial customers under a new relationship with an accountable care organization. We also have extended our menu to now offer specialized pharmacogenomics testing for personalized medicine through Genomas.
“We expect that this continued expansion of our customer base and products, combined with an increasing number of contracts with various payers, will enable us to grow our 2017 revenues to levels that more closely resemble years prior to 2016,” Mr. Lagan concluded.
As previously announced, the Company closed on an offering of preferred stock on December 20, 2016. The Company currently has 84,011,068 shares of common stock outstanding.
Globalstar, Inc. (GSAT) recently recorded -0.62 percent change and currently at $1.6 is 153.97 percent away from its 52-week low and down -46.67 percent versus its peak. It has a past 5-day performance of -9.6 percent and trades at an average volume of 6.77M shares. The stock has a 1-month performance of 88.24 percent and is 1.27 percent year-to-date as of the recent close. There were about 1.02B shares outstanding which made its market cap $1.63B. The share price is currently 13.84 percent versus its SMA20, 48.2 percent versus its SMA50, and 16.86 percent versus its SMA200.
Dec. 23, 2016 — Globalstar, Inc. (GSAT) is very pleased to announce that the Federal Communications Commission adopted a Report and Order based on Globalstar’s Revised Proposal for terrestrial authority over the Company’s 11.5 MHz of licensed 2.4 GHz spectrum.
Globalstar expects the Commission to release the order. These newly adopted rules will make more broadband spectrum available to, and improve wireless broadband service for, consumers in the United States.